Allay Therapeutics appointed new additions to its clinical and scientific advisory boards, according to an Oct. 24 news release.
The clinical advisory board provides guidance on the company's ATX101 product for pain management after total knee replacement. The scientific advisory board is focused on nonclinical development and pipeline opportunities.
New additions to the clinical advisory board are:
Sabry Ayad, MD
Ron Burch, MD, PhD
David Dalury, MD
Hemant Pandit
Christine Sang, MD
New additions to the scientific advisory board are:
Christine Allen, PhD
Ron Burch, MD, PhD
Joachim Kohn, PhD
Louis L. Radulovic, PhD
Arthur Tipton, PhD